Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Sanofi Aventis, Biotronik, Boston Scientific/Guidant (Europe), Medtronic, Merck, and St. Jude Medical
- National Institutes of Health (R01HL092577, R01HL104156, 1K24HL105780)
- American Heart Association (13EIA14220013)
- iRhythm
- Medtronic, St. Jude Medical, Biosense Webster, and Boston Scientific
- National Institutes of Health (HL103800)
- Netherlands Organization for Scientific Research (016.136.055)
This publication has 102 references indexed in Scilit:
- Treatment of Atrial Fibrillation by the Ablation of Localized SourcesJACC, 2012
- Meta-analysis identifies six new susceptibility loci for atrial fibrillationNature Genetics, 2012
- Atrial Conduction Slows Immediately Before the Onset of Human Atrial FibrillationJACC, 2012
- Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial FibrillationJAMA, 2010
- Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillationCardiovascular Research, 2010
- Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: Implications for disease progression and response to catheter ablationHeart Rhythm, 2010
- Common variants in KCNN3 are associated with lone atrial fibrillationNature Genetics, 2010
- A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic strokeNature Genetics, 2009
- Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestryNature Genetics, 2009
- Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort studyThe Lancet, 2009